Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA.
Med Sci Monit. 2023 Jan 1;29:e939357. doi: 10.12659/MSM.939357.
There is hope that 2023 could bring regulatory approval, licensing, and implementation programs for safe and effective adjuvanted vaccines to prevent malaria. Clinical trials involving the two leading adjuvanted malaria vaccines directed to the Plasmodium falciparum circumsporozoite protein (PfCSP) are ongoing. These vaccines are RTS,S/ASO1 (Mosquirix®) and R21/Matrix-M™ (R21/MM). This year, the World Health Organization (WHO) updated its strategy to eradicate malaria by 2030. The hope is that major advances in global health security from effective malarial vaccines could reduce morbidity and save the lives of millions of people living in malaria-endemic countries to achieve the goals recommended by the WHO. This Editorial aims to give an update on recent findings from key clinical trials on the safety and efficacy of RTS,S/ASO1 and R21/MM malaria vaccines and to provide an insight into the importance of key ongoing clinical trials that will report in early 2023.
有希望的是，2023 年能够为安全有效的含佐剂疫苗的监管批准、许可和实施计划提供保障，以预防疟疾。目前正在进行两项针对恶性疟原虫环子孢子蛋白（PfCSP）的领先含佐剂疟疾疫苗的临床试验。这两种疫苗是 RTS,S/ASO1（Mosquirix®）和 R21/Matrix-M™（R21/MM）。今年，世界卫生组织（WHO）更新了其在 2030 年消灭疟疾的战略。人们希望，有效的抗疟疾疫苗在全球卫生安全方面取得重大进展，能够降低发病率，挽救生活在疟疾流行国家的数百万人的生命，从而实现世界卫生组织推荐的目标。本社论旨在介绍 RTS,S/ASO1 和 R21/MM 疟疾疫苗的安全性和有效性的关键临床试验的最新发现，并深入了解将在 2023 年初报告结果的关键正在进行的临床试验的重要性。
